AIMS: In ambulatory patients with coronary artery disease (CAD) we aimed to evaluate the
diagnostic performance of mid-regional pro-adrenomedullin (MR-proADM) for the detection …

Left ventricular hypertrophy (LVH) is a risk factor for cardiovascular disease. Elevated
natriuretic peptides in LVH have spurred interest that biomarkers may play a role in …

Abstract BACKGROUND Midregional proadrenomedullin (MR-proADM) is a newly identified
prognostic marker in heart failure. We evaluated the prognostic impact of MR-proADM in a …

Background Biomarkers may contribute to risk stratification in coronary heart disease (CHD).
We examined whether plasma midregional proadrenomedullin (MR-proADM) concentration …

Background and Objectives: the cardiovascular adverse events including mortality and heart
failure, persist significantly during the first months after the acute phase of ST-segment …

Background Diabetes mellitus (DM) is associated with an adverse outcome in heart failure
(HF). Increased concentrations of midregional proadrenomedullin (MR-proADM) have been …

Background: MRproADM and MRproANP can be used as diagnostic and prognostic
markers in heart failure. Aim: The objective was to identify confounding factors for the …

Objective Experimental studies have shown that adrenomedullin (ADM) has an important
role in circulatory homeostasis. Mid-regional pro-ADM (MR-proADM) is a stable form of …

Objective To assess the cardiovascular prognostic value of mid-regional pro-
adrenomedullin (MR-proADM) and compare this with B-type natriuretic peptide (BNP) and N …

Abstract Background: Midregional proadrenomedullin (MR-proADM) is emerging as a
prognostic biomarker for detecting the failure of multiple organs. Establishment of …